Masten-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Usage

1. Verify the ampoule's labelling, lot number, and expiry date before breaking the seal — the enanthate ester's extended shelf-life makes lot traceability important for multi-cycle stock management.
2. Allow the ampoule to reach room temperature naturally (20–25 °C) before administration; oil-based enanthate formulations at lower temperatures have increased viscosity, which slows draw-up and can cause injection-site discomfort.
3. Draw the full 1ml volume using an 18–21G draw needle; switch to a 23–25G injection needle (1–1.5 inch) for intramuscular delivery into the gluteus medius or vastus lateralis, matching needle length to injection-site adipose depth.
4. Administer via slow intramuscular injection over 20–30 seconds — the oil vehicle must disperse into the muscle to form the depot from which the enanthate ester is absorbed progressively over 10–11 days.
5. Rotate injection sites systematically across a twice-weekly schedule; because the oil depot takes days to fully absorb, re-injecting the same site before clearance may cause localised accumulation and tissue irritation.
6. Log each injection date and site; use the 10–11 day half-life as the pharmacokinetic reference point when timing blood work for mid-cycle plasma level assessment — draw approximately 72 hours post-injection to capture near-peak values.

Warnings

Frequently asked questions

What is the half-life of Drostanolone Enanthate in Masten-200?

Drostanolone Enanthate carries a half-life of approximately 10–11 days, derived from enanthic acid ester kinetics in oil-based depots. This is roughly four to five times longer than Drostanolone Propionate (2–3 days), enabling a twice-weekly injection schedule while maintaining stable plasma concentrations without sharp hormonal peaks or troughs between doses.

How quickly does Drostanolone Enanthate reach peak plasma concentration after injection?

Peak serum levels (Cmax) following intramuscular injection of an enanthate-esterified androgen in oil typically occur within 48–72 hours post-administration. The oil depot releases compound gradually as serum carboxylesterases cleave the enanthate chain; this delayed Tmax is slower than propionate forms, which peak within 24 hours, and reflects the longer lipophilic chain of the C7 enanthate ester.

What injection frequency does the pharmacokinetic profile of Masten-200 support?

The 10–11 day half-life of Drostanolone Enanthate supports a twice-weekly injection schedule — typically every 3–4 days. This frequency maintains steady-state plasma levels without the daily or every-other-day injections required with propionate variants, making Masten-200 more suitable for athletes who prioritise cycle convenience alongside hormonal consistency.

Why are single-dose 1ml ampoules used for Masten-200 rather than a multi-dose vial?

Single-dose glass ampoules eliminate the contamination risk associated with repeated needle penetration through a rubber stopper in multi-dose vials. Each 1ml ampoule is hermetically sealed and sterile at point of use; once opened, the full dose is administered immediately, with no residual product exposed to atmospheric or microbial ingress. BM Pharmaceuticals specifies this format specifically for sterility assurance in oil-based depot formulations.

How should Masten-200 ampoules be stored to preserve the enanthate ester integrity?

Store Masten-200 ampoules at room temperature (15–25 °C), away from direct light and moisture. Oil-based ester injectables are sensitive to thermal cycling; refrigeration can increase viscosity and cause crystallisation of the vehicle, while elevated heat accelerates ester hydrolysis. Sealed ampoules within their original carton maintain stability across the labelled shelf-life when stored under recommended conditions. (2) angle_used

Manufacturer

The quality infrastructure underlying Masten-200 is most precisely examined through the analytical challenge that a single-ester oil-based injectable at 200 mg/ml presents: declared concentration must be independently verified at batch level, not extrapolated from formulation records. BM Pharmaceuticals addresses this through reversed-phase HPLC quantification, in which Drostanolone Enanthate in the finished oil matrix is separated, identified, and quantified against a certified pharmacopoeial reference standard — a method that detects concentration deviations that visual inspection or density measurements cannot. This approach is particularly relevant for an enanthate-esterified compound: the molecular weight contribution of the enanthate chain (C7 acyl group) means that mass-based concentration calculations require ester-corrected quantification to reflect actual deliverable Drostanolone per millilitre. Parallel to potency testing, each batch of Masten-200 is subjected to LAL (Limulus Amebocyte Lysate) endotoxin testing — a mandatory sterility parameter for intramuscular depot formulations where pyrogenic contamination cannot be visually detected in an oil vehicle. The LAL test quantifies bacterial endotoxin load against defined pharmacopoeial limits, providing objective release data rather than process assumption. These two verification layers — HPLC potency and LAL endotoxin — form the release checkpoint that every Masten-200 batch must satisfy before authorised dispatch from BM Pharmaceuticals' GMP-registered facility.